Company Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases.
The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma.
Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2014 |
| IPO Date | Jun 22, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 463 |
| CEO | Dr. Christian Martin Itin Ph.D. |
Contact Details
Address: The Mediaworks, 191 Wood Lane London, X0 W12 7FP United Kingdom | |
| Phone | 44 20 3829 6230 |
| Website | autolus.com |
Stock Details
| Ticker Symbol | AUTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001730463 |
| CUSIP Number | 05280R100 |
| ISIN Number | US05280R1005 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christian Martin Itin Ph.D. | Chief Executive Officer and Director |
| Dr. Martin Pule M.D., MBBS | Founder, Senior Vice President and Chief Scientific Officer |
| Robert F. Dolski | Senior Vice President and Chief Financial Officer |
| Christopher Vann | Senior Vice President and Chief Operating Officer |
| David Brochu | Senior Vice President and Chief Technical Officer |
| Alexander Swan | Senior Vice President and Chief Human Resources Officer |
| Brent Rice | Senior Vice President, Chief Commercial Officer and Site Head of US |
| Olivia Manser | Director of Investor Relations |
| Alex Driggs | Senior Vice President of Legal Affairs and General Counsel and Secretary |
| Dr. Chris Williams | Senior Vice President and Chief Business Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | 8-K | Current Report |
| Mar 28, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 25, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Mar 15, 2024 | 8-K/A | [Amend] Current report |
| Mar 14, 2024 | 8-K | Current Report |
| Feb 23, 2024 | D | Notice of Exempt Offering of Securities |
| Feb 21, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |